NCT05890118View on ClinicalTrials.gov

Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Stelara

A commercial formulation of ustekinumab for SC control (0.5mg)

COMBINATION_PRODUCT

RT-111 (0.5mg)

RaniPill capsule containing ustekinumab with a dose of 0.5mg

COMBINATION_PRODUCT

RT-111 (0.75mg)

RaniPill capsule containing ustekinumab with a dose of 0.75mg

Trial Locations (1)

Unknown

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

RANI Therapeutics
All Listed Sponsors
lead

RANI Therapeutics

INDUSTRY

NCT05890118 - Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule | Biotech Hunter | Biotech Hunter